

A practical guide on the assessment and management of testosterone deficiency in adult men



Based on the 2017 British Society for Sexual Medicine (BSSM) guidelines on adult testosterone deficiency, with statements for UK practice¹

Why does it occur?

Testosterone deficiency (TD), also known as hypogonadism, may result from:²⁻⁴

- Problems with the testes [primary (hypergonadotropic) TD]
- Problems with the hypothalamus and pituitary gland [secondary (hypogonadotropic) TD]
- Problems with the hypothalamus/pituitary and testes (combined primary and secondary TD)
- Impaired action/suppression of testosterone

How is it diagnosed?

- The diagnosis of symptomatic TD requires the presence of characteristic signs and symptoms,^{2,5-8} PLUS reduced serum concentrations of total testosterone (TT) or free testosterone (FT)⁵

Psychological

- Changes in mood (e.g. anger, irritability, sadness, depression)
- Decreased well-being/poor self-rated health
- Diminished cognitive function (including impaired concentration, verbal memory and spatial performance)

Cardiometabolic

- Increased body mass index (BMI)/obesity
- Visceral obesity
- Metabolic syndrome
- Insulin resistance and type 2 diabetes


Physical

- Decreased body hair
- Gynaecomastia
- Decreased muscle mass and strength
- Hot flushes/sweats
- Sleep disturbances
- Fatigue
- Osteoporosis/height loss/low trauma fractures

Sexual

- Delayed puberty
- Small testes
- Infertility
- Decreased sexual desire and activity
- Decreased frequency of sexual thoughts
- Erectile dysfunction (ED)
- Delayed ejaculation
- Decreased volume of ejaculate
- Decreased or absent morning/night-time erections

- The **3** most common symptoms of TD are ED, loss of early morning erections and low sexual desire – men often present with sexual dysfunction and a desire for treatment



Who should be screened for TD?

- Adult men with consistent and multiple signs of TD
- All men presenting with ED, loss of spontaneous erections or low sexual desire
- All men with type 2 diabetes mellitus, BMI >30 kg/m² or waist circumference >102 cm (40.2 inches)
- All men on long-term opiate, antipsychotic or anticonvulsant medication

History taking

- **Enquire** about previous and current prescription and non-prescription drug use⁷
- **Assess and exclude** systemic illness, ongoing acute disease, malabsorption and malnutrition⁷
- **Consider** the use of validated questionnaires, such as the Androgen Deficiency in the Ageing Male (ADAM) questionnaire (included in the Sexual Advice Association SMART SAA app, available at: <http://sexualadviceassociation.co.uk/>), or the Ageing Males' Symptoms (AMS) Scale (available at: http://www.issam.ch/AMS_English.pdf) – information on interpreting the scores can be found at: <http://zeg-berlin.de/wp-content/uploads/2017/01/norm.pdf>

Physical examination

- **Measure** height, weight, BMI and waist circumference⁵
- **Assess** the degree of body hair (including facial and pubic)⁵
- **Examine** for the presence and degree of breast enlargement, and abnormalities of the penis, testicles^{5,7} and scrotum⁵
- **Check** the prostate via digital rectal examination (DRE)⁷
- **Arrange** blood investigations, including prostate-specific antigen (PSA), haematocrit, and appropriate tests according to physical findings and to determine cardiovascular (CV) risk

Laboratory diagnosis

Serum testosterone – measure between 7–11 am,^{5,7} with a reliable method, on at least 2 occasions,⁷ preferably 4 weeks apart. Fasting levels should be obtained where possible, as recommended by the European Association of Urology (EAU).⁷

If low/borderline, measure LH* and FSH,** plus SHBG to calculate FT.

FT – an online FT calculator and downloadable app, sponsored by the Primary Care Testosterone Advisory Group (PCTAG), can be found at <http://www.pctag.uk/testosterone-calculator/>

FSH – follicle-stimulating hormone, LH – luteinising hormone, SHBG – sex hormone-binding globulin
*LH to differentiate primary from secondary TD. **FSH is only necessary if fertility is an issue.

Main contraindications to testosterone therapy⁷


- Prostate cancer (locally advanced or metastatic)
- Male breast cancer
- An active desire to have children
- Haematocrit >54%
- Severe chronic heart failure [New York Heart Association (NYHA) class IV]

Testosterone therapy and ED

- Testosterone therapy (T Therapy) is appropriate for treating ED,^{8,9} particularly at TT levels <8 nmol/L,⁸ and for salvaging ED treatment failures with oral medication, particularly at TT levels <10.4 nmol/L¹⁰
- T Therapy reduces the need for more invasive and expensive second- and third-line treatments¹¹
- A PDE5i can be prescribed for all men with ED when commencing T Therapy as long as there are no contraindications, because T Therapy can take many months to correct ED

PDE5i – phosphodiesterase type 5 inhibitor

Diagnosing and managing TD in adult men^{2,7,9,12,13}



Adapted from Minhas and Mulhall, 2017.¹³

AI – aromatase inhibitor, CV – cardiovascular, CVD – cardiovascular disease, FSH – follicle-stimulating hormone, FT – free testosterone, HCG – human chorionic gonadotropin, LH – luteinising hormone, MRI – magnetic resonance imaging, PSA – prostate-specific antigen, SERM – selective oestrogen receptor modulator, SHBG – sex hormone-binding globulin, T Therapy – testosterone therapy, TT – total testosterone

*For men with TT levels <5.2 nmol/L plus low LH and FSH or increased prolactin levels, refer to endocrinology or arrange a pituitary MRI scan to exclude a pituitary adenoma.^{2,14}

**These drugs should not be used if pituitary function is compromised. SERMs and Als are not currently licensed for TD.

Testosterone therapy

- The patient should be fully informed about the expected benefits and side effects of T Therapy, to facilitate a joint decision on treatment choice

Testosterone therapy options^{6,15}

Formulation	Route of administration	Frequency of administration	Advantages	Disadvantages
Testosterone 1%, 1.62%* and 2% gel available *1.62% = 16.2 mg/g	Transdermal gel 1% (sachets/tubes) 1.62%* (pump) 2% (pump) *1.62% = 16.2 mg/g	<ul style="list-style-type: none"> • Applied daily¹⁶ • May require dose titration 	<ul style="list-style-type: none"> • Fast onset • Provides uniform and normal serum levels for 24 hours⁷ 	<ul style="list-style-type: none"> • Skin irritation at application site • Potential for interpersonal transfer • Compliance may be an issue long-term
Testosterone undecanoate	Intramuscular injection	Every 10–14 weeks, adjusted to maintain trough testosterone >12 nmol/L	<ul style="list-style-type: none"> • Steady state levels • Reduced frequency of administration improves compliance 	<ul style="list-style-type: none"> • Possible injection site pain/reaction¹⁷
Testosterone enantate	Intramuscular injection	Every 2–3 weeks	Can be administered every 3–6 weeks for maintenance, according to individual requirement ¹⁸	<ul style="list-style-type: none"> • Levels fluctuate • Possible injection site pain/reaction¹⁸
Mix of 4 testosterone esters (including propionate) as Sustanon 250	Intramuscular injection	Usually administered every 3 weeks May cause a reaction at the injection site ¹⁹		

Adapted from Hackett et al. (2017)⁶ and Dohle et al. (2017)¹⁵

- When considering side effects and drug withdrawal times, physicians should bear in mind the pharmacodynamic and pharmacokinetic properties of the injectable versus the transdermal formulations

References

- Hackett G et al. The British Society for Sexual Medicine guidelines on adult testosterone deficiency with statements for UK practice. *J Sex Med* 2017;14:1504-23.
- Khera M et al. Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). *J Sex Med* 2016;13:1787-804.
- Bawor M et al. Testosterone suppression in opioid users: a systematic review and meta-analysis. *Drug Alcohol Depend* 2015;149:1-9.
- Morrison D et al. Testosterone levels during systemic and inhaled corticosteroid therapy. *Respir Med* 1994;88:659-63.
- Lunenfeld B et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. *Aging Male* 2015;18:5-15.
- Hackett G et al. UK policy statements on testosterone deficiency. *Int J Clin Pract* 2017 Mar;71(3-4). doi: 10.1111/ijcp.12901. Epub 2017 Mar 20.
- Dohle GH et al. Guidelines on Male Hypogonadism. European Association of Urology 2017. Available at: <http://uroweb.org/guideline/male-hypogonadism/> (Accessed September 2017).
- Dean JD et al. The International Society for Sexual Medicine's process of care for the assessment and management of testosterone deficiency in adult men. *J Sex Med* 2015;12:1660-86.
- British Society of Sexual Medicine. Guidelines on the management of sexual problems in men: the role of androgens 2010. Available at: <http://bssm.org.uk/> (Accessed June 2017).
- Buvat J et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). *J Sex Med* 2011;8:284-93.
- Lowe G et al. Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction. *Ther Adv Urol* 2009;1:235-42.
- ISSM (online). ISSM quick reference guide on testosterone deficiency for men. September 2015. Available at: <http://www.issm.info/education/clinical-guidelines/> (Accessed March 2017).
- Minhas S & Mulhall J (Eds). Male sexual dysfunction. A clinical guide (2017). John Wiley and Sons Ltd, West Sussex, UK
- Bhasin S et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2010;95:2536-59.
- Dohle GH et al. EAU guidelines on male hypogonadism (Limited text update March 2017). Available at: <http://uroweb.org/guideline/male-hypogonadism/?type=pocket-guidelines> (Accessed September 2017).
- Besins Healthcare (UK) Ltd. Testogel Summary of Product Characteristics. May 2016.
- Bayer PLC. Nebido 1000mg/4mL, solution for injection Summary of Product Characteristics. August 2017.
- Alliance Pharmaceuticals. Testosterone enantate ampoules Summary of Product Characteristics. October 2016.
- Aspen Pharma Trading Limited. Sustanon 250 Summary of Product Characteristics. December 2016.